The NewStandard ceased publishing on April 27, 2007.

$5.5 M Awarded to Victims of Diet Drug ‘Fen-phenâ€TM as Suits Continue

by Pranjal Tiwari

Mar. 31, 2005 – Pharmaceutical company Wyeth will have to pay $5.5 million in damages to two plaintiffs as lawsuits involving withdrawn diet drug Pondimin continue to make their way into and through the courts. A jury in Philadelphia awarded $5 million in damages to Isabelle Vega and $500,000 to Camille Olsen, finding that Wyeth’s product had caused damage to the heart valves of both plaintiffs.

Email to a Friend
Print-friendly Version
Add to My Morning Paper

The same day saw two other cases decided in favor of Wyeth.

In 1997, at the FDA’s urging, Wyeth withdrew two drugs -- Pondomin and Redux, or fenfluramine and dexfenfluramine, respectively -- off of the market. The FDA had separately approved them in 1959 and 1973 as appetite suppressants available on prescription for the "short term… management of obesity." However, a combination of either drug with another drug, phentermine, in a cocktail known as "fen-phen," was later made available for unapproved, "off-label" use. Studies found fen-phen to cause dangerous heart valve irregularities.

Last month Wyeth announced it expects to pay up to $21 billion in legal fees and payouts from lawsuits brought by former fen-phen users. The company is still facing around 60,000 lawsuits related to the health effects of the drugs.

Send to Friends Respond to Editors or Reporter

The NewStandard ceased publishing on April 27, 2007.

Pranjal Tiwari is a contributing journalist.

Recent contributions by Pranjal Tiwari: